New drug aims to cut steroid use in rare hormone disorder

NCT ID NCT04544410

Terminated Disease control Sponsor: Spruce Biosciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a daily tablet called Tildacerfont in 100 adults with classic congenital adrenal hyperplasia, a condition where the body can't make certain hormones properly. The goal was to see if the drug could safely reduce the high doses of steroids patients need to take. The trial was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tildacerfont (also called SPR001), a daily tablet
What this could lead to: If it works, this could help people with congenital adrenal hyperplasia take lower doses of steroids while still controlling their condition.
What could go wrong: This trial was terminated early, so results are limited. It is a small Phase 2 study, and the drug may not prove effective or safe in larger groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLASSIC CONGENITAL ADRENAL HYPERPLASIA DUE TO 21-HYDROXYLASE DEFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adrenal gland disorder classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency congenital adrenal hyperplasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CONGENITAL ADRENAL HYPERPLASIA

Contacts and locations

Show contact details

Locations

Spruce Biosciences Clinical Site

Ann Arbor, Michigan, 48109, United States
Spruce Study Site

Birmingham, Alabama, 35294, United States
Spruce Study Site

Los Angeles, California, 90027, United States
Spruce Study Site

San Diego, California, 92123, United States
Spruce Study Site

Indianapolis, Indiana, 46202, United States
Spruce Study Site

Baltimore, Maryland, 21287, United States
Spruce Study Site

Minneapolis, Minnesota, 55454, United States
Spruce Study Site

New Brunswick, New Jersey, 08901, United States
Spruce Study Site

Canton, Ohio, 44718, United States
Spruce Study Site

Cincinnati, Ohio, 45219, United States
Spruce Study Site

Cleveland, Ohio, 44195, United States
Spruce Study Site

Columbus, Ohio, 43210, United States
Spruce Study Site

Philadelphia, Pennsylvania, 19104, United States
Spruce Study Site

Philadelphia, Pennsylvania, 19107, United States
Spruce Study Site

Philadelphia, Pennsylvania, 19140, United States
Spruce Study Site

Providence, Rhode Island, 02903, United States
Spruce Study Site

Columbia, South Carolina, 29203, United States
Spruce Study Site

Fort Worth, Texas, 76104, United States
Spruce Study Site

Blacktown, Australia
Spruce Study Site

Brisbane, 4029, Australia
Spruce Study Site

Elizabeth Vale, Australia
Spruce Study Site

Parkville, Australia
Spruce Study Site

Curitiba, Brazil
Spruce Study Site

São Paulo, Brazil
Spruce Study Site

Ottawa, Ontario, Canada
Spruce Study Site

Sherbrooke, Quebec, J1H 5N4, Canada
Spruce Study Site

Tallinn, Estonia
Spruce Study Site

Tartu, Estonia
Spruce Study Site

Munich, Germany
Spruce Study Site

Roma, Italy
Spruce Study Site

Riga, Latvia
Spruce Study Site

Kaunas, Lithuania
Spruce Study Site

Krakow, Poland
Spruce Study Site

Warsaw, Poland
Spruce Study Site

Bucharest, Romania
Spruce Study Site

Seoul, South Korea
Spruce Study Site

Barcelona, Spain
Spruce Study Site

Madrid, Spain
Spruce Study Site

Seville, Spain
Spruce Study Site

Tarragona, Spain
Spruce Study Site

Stockholm, Sweden
Spruce Study Site

Istanbul, Turkey (Türkiye)
Spruce Study Site

Birmingham, B15 2GW, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.